InvestorsHub Logo

GMason

02/24/20 9:49 AM

#9692 RE: abc1938 #9689

It’s just strange that they never formed a partnership. Engel is an extreme control freak from what I gather, hence everything under one roof, stubbornly trying to keep selling trailblazer that he knows no one wants but because it was their idea they are reluctant to let it go. At this point they should be growing only top selling SKU’s. Oh wait that may only be one or two strains, lol. Ok they need better genetics flat out. However back to your point yes they need a beverage partner and we all would benefit greatly from it.

Hunchbackgeek

02/24/20 1:02 PM

#9693 RE: abc1938 #9689

Yes, this is already in the works abc1938. OGI

Hunchbackgeek

02/24/20 1:14 PM

#9694 RE: abc1938 #9689

OGI OrganiGram's Biosynthesis Disruptive Technology......

Organigram is one of only two Canadian LPs to make a strategic investment in biosynthesis – a disruptive production technology.

What is Biosynthesis?
Biosynthesis is the production of molecules using living cells. By incorporating the instructions for producing a specific molecule into the genetic code of a simple host organism—e.g., bacteria, yeast, or algae—these organisms can produce nearly any molecule. The host cells are essentially ‘factories’.

Why Biosynthesis?
The principal cannabinoids—THC and CBD—make up just ~two to five per cent of the cannabis plant, while minor cannabinoids and terpenes—hundreds of them—comprise less than 0.1 per cent. As such, 95 per cent of the plant generally ends up as waste through current methods for manufacturing, which rely on planting, growing, and harvesting large quantities of cannabis plants and then extracting and purifying their active compounds. The process often yields a complex chemical mixture of variable and inconsistent composition.

Biosynthesis has the potential to create cannabinoids at large scale at a fraction of the cost of traditional cultivation.

Organigram has invested in Hyasynth Biologicals Inc. a Montreal-based biotechnology company and leader in the field of cannabinoid science and biosynthesis. Hyasynth has developed a disruptive technology using proprietary yeast strains and patent-pending enzymes to naturally produce cannabinoids without growing the cannabis plant.

The Opportunity


Biosynthesis vs Traditional Cultivation:

~ Reduced operating and capital costs
~ Scalable, consistent, superior purity and quality
~ Production of minor cannabinoids just as feasible as major ones
~ Able to meet even more rigorous standards of CPG and Pharma
~ Smaller environmental footprint

While Organigram believes there will always be a sizeable market for the premium dried flower produced at its facility, working with Hyansynth changes assumptions about scale, speed and precision to produce the highest margin products such as extract-based medical products and a range of adult-use recreational products such as edibles and beverages.

In addition to the investment, Organigram has the right to purchase 25 per cent of the cannabinoid offtake from Hyasynth at a discount to market prices.

The nano-emulsion technology

The nano-emulsion technology is anticipated to be stable to temperature variations, mechanical disturbance, salinity, pH, and sweeteners.

The Company’s researchers have also recently developed a way to transform this emulsification system into a solid form, turning it into a dissolvable powder. This shelf-stable, water-compatible and unflavoured cannabinoid nano-emulsion formulation is also expected to begin to be absorbed within 10 to 15 minutes when ingested after added to a liquid.

The powdered formulation will offer consumers a measured dose of cannabinoids which they can then add to liquid, such as a beverage of their choice, while also offering the discretion, portability and shelf life expected of a dried powder formulation.

The Company is planning to launch a variety of dried powder formulation beverage products in the second quarter of calendar 2020 and is actively seeking a strategic partner with proven experience in beverage product development to take advantage of the liquid formulation it has developed.

FOR MORE INFORMATION, SOURCE: https://www.organigram.ca/innovation#biosynthesis

.